These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 22260415)

  • 1. Bioengineered nisin derivatives with enhanced activity in complex matrices.
    Rouse S; Field D; Daly KM; O'Connor PM; Cotter PD; Hill C; Ross RP
    Microb Biotechnol; 2012 Jul; 5(4):501-8. PubMed ID: 22260415
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bioengineered nisin A derivatives with enhanced activity against both Gram positive and Gram negative pathogens.
    Field D; Begley M; O'Connor PM; Daly KM; Hugenholtz F; Cotter PD; Hill C; Ross RP
    PLoS One; 2012; 7(10):e46884. PubMed ID: 23056510
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The generation of nisin variants with enhanced activity against specific gram-positive pathogens.
    Field D; Connor PM; Cotter PD; Hill C; Ross RP
    Mol Microbiol; 2008 Jul; 69(1):218-30. PubMed ID: 18485077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Saturation mutagenesis of lysine 12 leads to the identification of derivatives of nisin A with enhanced antimicrobial activity.
    Molloy EM; Field D; O' Connor PM; Cotter PD; Hill C; Ross RP
    PLoS One; 2013; 8(3):e58530. PubMed ID: 23505531
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bioengineering nisin to overcome the nisin resistance protein.
    Field D; Blake T; Mathur H; O' Connor PM; Cotter PD; Paul Ross R; Hill C
    Mol Microbiol; 2019 Mar; 111(3):717-731. PubMed ID: 30537404
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intensive mutagenesis of the nisin hinge leads to the rational design of enhanced derivatives.
    Healy B; Field D; O'Connor PM; Hill C; Cotter PD; Ross RP
    PLoS One; 2013; 8(11):e79563. PubMed ID: 24244524
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Investigation of combinations of rationally selected bioengineered nisin derivatives for their ability to inhibit Listeria in broth and model food systems.
    Nyhan L; Field D; Hill C; Callanan M; Begley M
    Food Microbiol; 2021 Oct; 99():103835. PubMed ID: 34119119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Studies with bioengineered Nisin peptides highlight the broad-spectrum potency of Nisin V.
    Field D; Quigley L; O'Connor PM; Rea MC; Daly K; Cotter PD; Hill C; Ross RP
    Microb Biotechnol; 2010 Jul; 3(4):473-86. PubMed ID: 21255345
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bioengineering of the model lantibiotic nisin.
    Field D; Cotter PD; Ross RP; Hill C
    Bioengineered; 2015; 6(4):187-92. PubMed ID: 25970137
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increasing the Antimicrobial Activity of Nisin-Based Lantibiotics against Gram-Negative Pathogens.
    Li Q; Montalban-Lopez M; Kuipers OP
    Appl Environ Microbiol; 2018 Jun; 84(12):. PubMed ID: 29625984
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bioengineering of a Nisin A-producing Lactococcus lactis to create isogenic strains producing the natural variants Nisin F, Q and Z.
    Piper C; Hill C; Cotter PD; Ross RP
    Microb Biotechnol; 2011 May; 4(3):375-82. PubMed ID: 21375711
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bio-Engineered Nisin with Increased Anti-
    Field D; Considine K; O'Connor PM; Ross RP; Hill C; Cotter PD
    Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33801752
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nisin M: a Bioengineered Nisin A Variant That Retains Full Induction Capacity but Has Significantly Reduced Antimicrobial Activity.
    O' Connor M; Field D; Grainger A; O' Connor PM; Draper L; Ross RP; Hill C
    Appl Environ Microbiol; 2020 Jul; 86(15):. PubMed ID: 32471915
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Bioengineered Nisin Derivative To Control Streptococcus uberis Biofilms.
    Pérez-Ibarreche M; Field D; Ross RP; Hill C
    Appl Environ Microbiol; 2021 Jul; 87(16):e0039121. PubMed ID: 34105992
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel bioengineered derivative of nisin displays enhanced antimicrobial activity against clinical Streptococcus agalactiae isolates.
    Hayes K; Field D; Hill C; O'Halloran F; Cotter L
    J Glob Antimicrob Resist; 2019 Dec; 19():14-21. PubMed ID: 31054335
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nisin resistance in Gram-positive bacteria and approaches to circumvent resistance for successful therapeutic use.
    Barbosa AAT; de Melo MR; da Silva CMR; Jain S; Dolabella SS
    Crit Rev Microbiol; 2021 May; 47(3):376-385. PubMed ID: 33689548
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of enhanced nisin derivatives in combination with food-grade oils or citric acid to control Cronobacter sakazakii and Escherichia coli O157:H7.
    Campion A; Morrissey R; Field D; Cotter PD; Hill C; Ross RP
    Food Microbiol; 2017 Aug; 65():254-263. PubMed ID: 28400011
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessing the ability of nisin A and derivatives thereof to inhibit gram-negative bacteria from the genus Thermus.
    Yeluri Jonnala BR; Feehily C; O'Connor PM; Field D; Hill C; Ross RP; McSweeney PLH; Sheehan JJ; Cotter PD
    J Dairy Sci; 2021 Mar; 104(3):2632-2640. PubMed ID: 33358792
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Resistance of Gram-positive bacteria to nisin is not determined by lipid II levels.
    Kramer NE; Smid EJ; Kok J; de Kruijff B; Kuipers OP; Breukink E
    FEMS Microbiol Lett; 2004 Oct; 239(1):157-61. PubMed ID: 15451114
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Nisin, a potential preservative for topical preparations].
    Valenta C; Bernkop-Schnürch A; Teltscher C
    Pharmazie; 1996 Feb; 51(2):119-22. PubMed ID: 8720808
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.